Table 2.
Sex, n | |
Male | 16 |
Female | 20 |
Median age at time of SBRT, years (range) | 67.5 (52–92) |
Median KPS at time of SBRT (range) | 80 (60–100) |
Median follow-up, months (range) | 15 (4–45) |
Median interval between treatments, months (range) | 22 (0–92) |
Initial Stage, n (%) | |
I–II | 16 (44%) |
III | 17 (47%) |
IV | 3 (8%) |
Type of initial radiation, n (%) | |
Definitive | 24 (67%) |
Postoperative | 7 (19%) |
Palliative | 5 (14%) |
Method of initial radiation, n (%) | |
Three-dimensional conformal | 25 (69%) |
IMRT | 11 (31%) |
Median dose of initial radiation, Gy (range) | 61.5 (30–79.2) |
Surgical history, n (%) | |
Wedge resection | 2 (6%) |
Lobectomy | 7 (19%) |
Chemotherapy with initial treatment, n (%) | |
Neo-adjuvant | 11 (31%) |
Concurrent | 14 (38%) |
Adjuvant | 7 (19%) |
Size of recurrence, long axis, cm (range) | 1.7 (0.6–3.8) |
Histology of recurrence, n (%) | |
Adenocarcinoma | 14 (39%) |
Squamous carcinoma | 12 (33%) |
NSCLC, NOS | 8 (22% |
Other | 2 (6%) |
Type of recurrence, n (%) | |
Isolated in-field recurrence | 11 (31%) |
Isolated out-of-field recurrence | 13 (36%) |
Recurrence in setting of disseminated disease | 12 (33%) |
SBRT dose and fractionation | |
50 Gy in 4 fractions | 26 (72%) |
40 Gy in 4 fractions | 6 (17%) |
Other | 4 (11%) |
Maximum point dose combined radiation treatments, Gy (range) | 81.5 (59.4–134.6) |
Abbreviations: IMRT = intensity-modulated radiation therapy; KPS = Karnofsky performance status; NSCLC = non–small cell lung cancer; SBRT = stereotactic body radiation therapy.